Author:
Skvortsov S, ,Dudás J,Eichberger P,Witsch-Baumgartner M,Loeffler-Ragg J,Pritz C,Schartinger V H,Maier H,Hall J,Debbage P,Riechelmann H,Lukas P,Skvortsova I
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan R, List MA, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29 (suppl): abstr 5500.
2. Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101: 2222–2229.
3. Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R (2006) A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 26: 585–590.
4. Begg AC (2012) Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol 22: 108–118.
5. Chen YW, Chu HC, Lin ZS, Shiah WJ, Chou CP, Klimstra DS, Lewis BC (2013) p16 stimulates CDC42-dependent migration of hepatocellular carcinoma cells. PLoS One 8: e69389.
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献